ClinicalTrials.gg
RecruitingNCT06952387PREMIUMUpdated Jul 14, 2025

PeRsonalized Blood prEssure Management on Postoperative Complications and Mortality in hIgh-risk Patients Undergoing Major Non-cardiac Surgery

An interventional study of Personalized blood pressure management and Routine blood pressure management in Hypotension, sponsored by Nanfang Hospital, Southern Medical University. Recruiting at 7 sites in China. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Nanfang Hospital, Southern Medical University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,624
Allocation
Randomized
Ages
65 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Hypotension with a site in China — 26 open to participants now, 29 under way, none of them phase 3. Hypotension · China.

Planned enrollment
2nd of 40
1,624 · median 129
Started
2025
with 8 others
No phase
26 of 59
12 open now
Primary completion
2027-12
later than 26 of 28 live
Registered
41st of 59
by date
Lead sponsor
3 of 59
Nanfang Hospital, Southern Medical University

Among the 59 studies in Hypotension with a site in China, this one is the 2nd largest by planned enrollment of the 40 interventional ones that give a count, is one of 9 that started in 2025, is one of 26 with no phase, reaches primary completion later than 26 of the 28 other live ones, and was the 41st registered.

Hypotension

892 studies on the registry are indexed under Hypotension; 199 are open to participants now.

Browse Hypotension studies →

Open to participants now

26 of the 59 studies in Hypotension with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 114 Hypotension studies recruiting now, 53 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 65 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypotension with a site in China, or all of them as a file.
02

Study summary

High-risk populations, particularly elderly individuals and patients with cardiovascular comorbidities, exhibit markedly elevated incidences of postoperative myocardial injury (MINS), acute kidney injury (AKI), and mortality.

Intraoperative hypotension (IOH), a pervasive clinical phenomenon affecting 40%-90% of surgical cases, Substantial observational evidence links IOH severity/duration to ischemic organ injuries (MINS, AKI) and long-term morbidity.Nevertheless, inherent limitations of observational designs-particularly residual confounding-preclude definitive causal inferences. Notably, randomized controlled trials (RCTs) investigating goal-directed hemodynamic interventions demonstrate inconsistent clinical benefits, underscoring the imperative to clarify causal mechanisms between IOH and organ injury. This causal ambiguity arises from two unresolved scientific questions:

(1) Threshold personalization deficit; (2) Therapeutic strategy limitations. In light of current evidence, perioperative hypotension management demands personalized strategies, the investigators propose a multicenter randomized controlled trial (RCT) that aims to clarify the clinical benefits of individualized blood pressure management.

Read the detailed description

Anesthesia- and surgery-related complications and mortality constitute a critical global public health burden. Annually, over 300 million surgical procedures are performed worldwide, with postoperative complications and mortality standing as predominant contributors to adverse outcomes. High-risk populations, particularly elderly individuals and patients with cardiovascular comorbidities, exhibit markedly elevated incidences of postoperative myocardial injury (MINS), acute kidney injury (AKI), and mortality. Refinement of perioperative management protocols-especially precision-guided hemodynamic control-has emerged as a pivotal strategy for optimizing patient prognosis.

Intraoperative hypotension (IOH), a pervasive clinical phenomenon affecting 40%-90% of surgical cases, is conventionally defined through either absolute thresholds (e.g., systolic blood pressure (SBP) \<90 mmHg or mean arterial pressure (MAP) \<65 mmHg) or relative reductions from baseline values (>20% decline). Its high prevalence and association with end-organ hypoperfusion have positioned IOH as a central concern in perioperative care. Substantial observational evidence links IOH severity/duration to ischemic organ injuries (MINS, AKI) and long-term morbidity. Nevertheless, inherent limitations of observational designs-particularly residual confounding-preclude definitive causal inferences. Notably, randomized controlled trials (RCTs) investigating goal-directed hemodynamic interventions demonstrate inconsistent clinical benefits, underscoring the imperative to clarify causal mechanisms between IOH and organ injury.

This causal ambiguity arises from two unresolved scientific questions:

  1. Threshold personalization deficit: Current paradigms predominantly apply population-based fixed thresholds (e.g., MAP ≥75-80 mmHg vs. ≥60 mmHg), disregarding interindividual hemodynamic variability. Although The Intraoperative Norepinephrine to Control Arterial Pressure (INPRESS) study used personalized blood pressure targets, its approach of measuring baseline blood pressure during a single clinic visit conflicts with current evidence. Research shows that 24-hour ambulatory monitoring is the most reliable method to capture an individual's true baseline blood pressure and daily fluctuations.
  2. Therapeutic strategy limitations: Conventional protocols emphasizing aggressive vasopressor use to achieve arbitrary pressure targets may inadvertently increase complications like anastomotic leakage and AKI. Furthermore, the multifactorial etiology of IOH-encompassing hypovolemia, vasoplegia, and impaired cardiac contractility-demands etiology-specific management algorithms rather than universal interventions.

In light of current evidence, perioperative hypotension management demands personalized strategies. To address this need, the investigators propose a multicenter randomized controlled trial (RCT) that pioneers the integration of ambulatory blood pressure monitoring (ABPM) with etiology-specific intervention protocols. This study aims to clarify the clinical benefits of individualized blood pressure management and establish high-quality evidence to advance precision anesthesia practices in perioperative care.

03

Conditions studied

  • Hypotension

Keywords

  • Blood Pressure
  • Postoperative complications
  • Mortality
  • Non-cardiac surgery
04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 65-90 yr;
  • Scheduled to undergo elective non-cardiac major surgery under general anesthesia (with an estimated surgery duration of ≥ 2 hours and an anticipated postoperative hospital stay of ≥ 2 days);
  • Patients with high cardiovascular risk, meeting at least one of the following conditions:

    1. History of stroke;
    2. History of coronary artery disease;
    3. History of congestive heart failure;
    4. History of peripheral arterial disease;
    5. Preoperative brain natriuretic peptide (BNP) ≥ 92 mg/L or N-terminal pro-brain natriuretic peptide (NT-proBNP) ≥ 300 ng/L;
    6. Preoperative cardiac troponin (cTn) or high-sensitivity cardiac troponin (hs-cTn) > upper reference limit;
    7. Hypertension requiring medication treatment;
    8. Diabetes requiring medication treatment;
    9. History of chronic kidney disease;
    10. Continuous smoking for 2 years or more, with interruptions of less than one month before the current hospital admission;
    11. Hypercholesterolemia;
    12. History of .

Exclusion criteria

Exclusion Criteria:

  • Refuse to participate this trial;
  • Inability to communicate in the preoperative period because of coma, profound dementia, or language barrier;
  • Severe uncontrolled hypertension before surgery (systolic blood pressure ≥ 180 mmHg, diastolic blood pressure ≥ 110 mmHg);
  • Severe hepatic dysfunction ( Class C); or severe renal dysfunction required preoperative dialysis; or (ASA) physical status ≥ V; or expectation lifespan ≤ 24h;
  • Unstable cardiovascular conditions: acute coronary syndrome, decompensated heart failure, severe arrhythmias, severe valvular heart disease;
  • Scheduled to undergo neurosurgical procedures, transplantation, vascular surgery;
  • Urgent surgery;
  • Diagnosed with sepsis or sepsis shock before surgery.
  • Requiring vasopressor treatment before surgery.
  • Unable to finish 24-hour automated blood pressure monitor;
  • Current participation in another interventional study.
  • Any condition deemed ineligible for participation by clinicians.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,624 participants (estimated)

Study arms

  • Other
    Control group

    In patients assigned to control group, clinicians were unaware of the results of preoperative automated 24-h blood pressure monitoring and thus managed blood pressure per institutional routine which generally is to maintain MAP above 60 mmHg. Routine blood pressure management started with the induction of anesthesia and lasted for 2 hours after surgery.

    Other: Routine blood pressure management

  • Experimental
    Intervention group

    In patients assigned to intervention group, clinicians were asked to maintain intraoperative MAP above the preoperative baseline MAP (with a maximum MAP target of 110 mmHg and a minimum MAP target of 65mmHg). Personalized blood pressure management started with the induction of anesthesia and lasted for 2 hours after surgery.

    Other: Personalized blood pressure management

Interventions

  • OtherPersonalized blood pressure management

    In patients assigned to personalized blood pressure management, clinicians were asked to maintain intraoperative MAP at least at the preoperative mean 24-hour MAP (with a maximum MAP target of 110 mmHg) from anesthesia induction to 2 hors after completion of surgery. If the preoperative mean 24-hour MAP was below 65mmHg, intraoperative MAP was maintained at least at 65mmHg. The mini fluid challenge (mini-FC, 100ml fluid infusion within 1minute) will be used to assess fluid responsiveness. A positive min-FC response (a stroke volume (SV) increase of at least 5%) will trigger fluid challenge (FC) administration (4ml/kg of balanced crystalloid or colloid within 10 minutes), whereas a negative min-FC response will trigger vasoactive drug administration.

    Also known as: Individualized blood pressure management

  • OtherRoutine blood pressure management

    In patients assigned to routine blood pressure management, clinicians were blinded to the results of preoperative automated 24-hour blood pressure monitoring, and thus managed blood pressure per institutional routine which generally is to maintain MAP above 60 mmHg. The mini fluid challenge (mini-FC, 100ml fluid infusion within 1minute) will be used to assess fluid responsiveness. A positive min-FC response (a stroke volume (SV) increase of at least 5%) will trigger FC administration (4ml/kg of balanced crystalloid or colloid within 10 minutes), whereas a negative min-FC response will trigger vasoactive drug administration.

    Also known as: Standard blood pressure management

06

What researchers measure

Primary outcomes

  1. A composite of postoperative complications and mortality within 30 days after surgery

    Defined as a composite of myocardial injury after non-cardiac surgery (MINS), myocardial infarction (MI), postoperative acute heart failure, non-fatal cardiac arrest, stroke, acute kidney injury (AKI), all-cause mortality.

    Time frame: Up to 30 days after surgery

Secondary outcomes

  1. The individual components of the primary composite outcome within 30 days after surgery

    The incidence of individual components of the primary composite outcome (MINS, MI, postoperative acute heart failure, non-fatal cardiac arrest, stroke, AKI and all-cause mortality).

    Time frame: Up to 30 days after surgery

  2. Proportion of ICU admission after surgery

    Proportion of patients admitted in intensive care unit after surgery.

    Time frame: Up to 30 days after surgery

  3. Length of stay in ICU after surgery

    For patients admitted to ICU after surgery, the investigators record the length of stay in the unit.

    Time frame: Up to 30 days after surgery

  4. Length of stay in the hospital after surgery

    Length of stay in the hospital after surgery.

    Time frame: Up to 30 days after surgery

  5. Other major postoperative complications within 30 days after surgery

    Defined as new onset medical events other than primary composite outcome that were deemed harmful and required therapeutic intervention, that is, Grade II or higher on the Clavien-Dindo classification.

    Time frame: Up to 30 days after surgery

  6. Time to first oral intake after surgery

    Defined as the time interval from surgery completion to first oral intake.

    Time frame: Up to 30 days after surgery

  7. Time to first flatus passage after surgery

    Defined as the time interval from surgery completion to first flatus passage

    Time frame: Up to 30 days after surgery

Other outcomes

  1. Overall survival after surgery

    Time from surgery to death

    Time frame: Up to 1 year after surgery

  2. Disability at 6 months after surgery

    Disability will assessed by 12-item self-administered World Health Organization disability assessment schedule 2.0 (WHODAS 2.0), which covers six domains of functioning with scores from 0 (no difficulty) to 4 (extreme difficulty) and a total score ranging from 0 to 48, with higher scores representing greater disability.

    Time frame: At 6 months after surgery

  3. Disability at 1 year after surgery

    Disability will assessed by 12-item self-administered World Health Organization disability assessment schedule 2.0 (WHODAS 2.0), which covers six domains of functioning with scores from 0 (no difficulty) to 4 (extreme difficulty) and a total score ranging from 0 to 48, with higher scores representing greater disability.

    Time frame: At 1 year after surgery

  4. Quality of life at 6 months after surgery

    Quality of life will assessed by a five-level EuroQol five-dimensional questionnaire (EQ-5D-5L). It is based on a descriptive system that defines health in terms of 5 dimensions: Mobility, SelfCare, Usual Activities, Pain/Discomfort, and Anxiety/ Depression. Each dimension has 5 response categories corresponding to no problems, slight problems, moderate problems, severe problems, and unable to do. The instrument is designed for self completion, and respondents also rate their overall health on the day of the interview on a 0-100 hash-marked, vertical visual analogue scale (EQ-VAS).

    Time frame: At 6 months after surgery

  5. Quality of life at 1 year after surgery

    Quality of life will assessed by a five-level EuroQol five-dimensional questionnaire (EQ-5D-5L). It is based on a descriptive system that defines health in terms of 5 dimensions: Mobility, SelfCare, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has 5 response categories corresponding to no problems, slight problems, moderate problems, severe problems, and unable to do. The instrument is designed for self completion, and respondents also rate their overall health on the day of the interview on a 0-100 hash-marked, vertical visual analogue scale (EQ-VAS).

    Time frame: At 1 year after surgery

07

Study locations

2 of 7 sites recruiting
08

References and documents

Publications

  • Wesselink EM, Kappen TH, Torn HM, Slooter AJC, van Klei WA. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review. Br J Anaesth. 2018 Oct;121(4):706-721. doi: 10.1016/j.bja.2018.04.036. Epub 2018 Jun 20. PubMed 30236233 ↗
  • Saugel B, Fletcher N, Gan TJ, Grocott MPW, Myles PS, Sessler DI; PeriOperative Quality Initiative XI (POQI XI) Workgroup Members. PeriOperative Quality Initiative (POQI) international consensus statement on perioperative arterial pressure management. Br J Anaesth. 2024 Aug;133(2):264-276. doi: 10.1016/j.bja.2024.04.046. Epub 2024 Jun 4. PubMed 38839472 ↗
  • Wanner PM, Wulff DU, Djurdjevic M, Korte W, Schnider TW, Filipovic M. Targeting Higher Intraoperative Blood Pressures Does Not Reduce Adverse Cardiovascular Events Following Noncardiac Surgery. J Am Coll Cardiol. 2021 Nov 2;78(18):1753-1764. doi: 10.1016/j.jacc.2021.08.048. PubMed 34711333 ↗
  • Marcucci M, Painter TW, Conen D, Lomivorotov V, Sessler DI, Chan MTV, Borges FK, Leslie K, Duceppe E, Martinez-Zapata MJ, Wang CY, Xavier D, Ofori SN, Wang MK, Efremov S, Landoni G, Kleinlugtenbelt YV, Szczeklik W, Schmartz D, Garg AX, Short TG, Wittmann M, Meyhoff CS, Amir M, Torres D, Patel A, Ruetzler K, Parlow JL, Tandon V, Fleischmann E, Polanczyk CA, Lamy A, Jayaram R, Astrakov SV, Wu WKK, Cheong CC, Ayad S, Kirov M, de Nadal M, Likhvantsev VV, Paniagua P, Aguado HJ, Maheshwari K, Whitlock RP, McGillion MH, Vincent J, Copland I, Balasubramanian K, Biccard BM, Srinathan S, Ismoilov S, Pettit S, Stillo D, Kurz A, Belley-Cote EP, Spence J, McIntyre WF, Bangdiwala SI, Guyatt G, Yusuf S, Devereaux PJ; POISE-3 Trial Investigators and Study Groups. Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery : An International Randomized Controlled Trial. Ann Intern Med. 2023 May;176(5):605-614. doi: 10.7326/M22-3157. Epub 2023 Apr 25. PubMed 37094336 ↗
  • Futier E, Lefrant JY, Guinot PG, Godet T, Lorne E, Cuvillon P, Bertran S, Leone M, Pastene B, Piriou V, Molliex S, Albanese J, Julia JM, Tavernier B, Imhoff E, Bazin JE, Constantin JM, Pereira B, Jaber S; INPRESS Study Group. Effect of Individualized vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery: A Randomized Clinical Trial. JAMA. 2017 Oct 10;318(14):1346-1357. doi: 10.1001/jama.2017.14172. PubMed 28973220 ↗
  • Nicklas JY, Bergholz A, Dake F, Pham HHD, Rabe MC, Schlichting H, Skrovanek S, Flick M, Kouz K, Fischer M, Olotu C, Izbicki JR, Mann O, Fisch M, Schmalfeldt B, Frosch KH, Renne T, Krause L, Zollner C, Saugel B. Personalised blood pressure management during major noncardiac surgery and postoperative neurocognitive disorders: a randomised trial. BJA Open. 2024 Jul 1;11:100294. doi: 10.1016/j.bjao.2024.100294. eCollection 2024 Sep. PubMed 39050403 ↗
  • Saugel B, Reese PC, Sessler DI, Burfeindt C, Nicklas JY, Pinnschmidt HO, Reuter DA, Sudfeld S. Automated Ambulatory Blood Pressure Measurements and Intraoperative Hypotension in Patients Having Noncardiac Surgery with General Anesthesia: A Prospective Observational Study. Anesthesiology. 2019 Jul;131(1):74-83. doi: 10.1097/ALN.0000000000002703. PubMed 30998509 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

Of 213 non-industry interventional studies with no phase under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 30 months is above that.

Counting every sponsor, half of 220 studies reached it within 12 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2025
First posted
Apr 30, 2025
StartActual
Jun 3, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06952387
Responsible party
Sponsor
First posted
Apr 30, 2025
Start date
Jun 3, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 14, 2025

Study contacts

Ke-Xuan Liu, MD
Contact
liukexuan705@163.com
13710684096
Shuang-Jie Cao, MD
Contact
caosjie1994@126.com
13651119431
Ke-Xuan Liu, MD
principal investigator · Nanfang Hospital, Southern Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion